Aclarion (Aclarion) EBIT per Share : $-11.65 (TTM As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Aclarion EBIT per Share?

Aclarion's EBIT per Share for the three months ended in Mar. 2024 was $-6.07. Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $-11.65.

During the past 3 years, the average EBIT per Share Growth Rate was 4.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Aclarion's EBIT per Share or its related term are showing as below:

ACON' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -17.7 Med: -6.75 Max: 4.2
Current: 4.2

During the past 5 years, the highest 3-Year average EBIT per Share Growth Rate of Aclarion was 4.20% per year. The lowest was -17.70% per year. And the median was -6.75% per year.

ACON's 3-Year EBIT Growth Rate is ranked worse than
57.17% of 509 companies
in the Healthcare Providers & Services industry
Industry Median: 8 vs ACON: 4.20

Aclarion's EBIT for the three months ended in Mar. 2024 was $-2.06 Mil.

Aclarion EBIT per Share Historical Data

The historical data trend for Aclarion's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aclarion EBIT per Share Chart

Aclarion Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT per Share

-8.94

-9.98

-9.96

-14.56

-7.73

Aclarion Quarterly Data
	Dec19	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBIT per Share	Get a 7-Day Free Trial											-2.38	-2.74	-1.56	-1.28	-6.07

Aclarion EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Aclarion's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-4.303	/	0.557
=	-7.73

Aclarion's EBIT per Share for the quarter that ended in Mar. 2024 is calculated as

	EBIT per Share		(Q: Mar. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-2.063	/	0.340
=	-6.07

EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-11.65

Aclarion (NAS:ACON) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Aclarion EBIT per Share Related Terms

Thank you for viewing the detailed overview of Aclarion's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Aclarion (Aclarion) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Aclarion Inc (NAS:ACON) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

8181 Arista Place, Suite 300, Broomfield, CO, USA, 80021

Website

http://www.aclarion.com

Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. Its product Nociscan is a SaaS platform that leverages MR Spectroscopy to noninvasively help physicians distinguish between painful and nonpainful discs in the spine. The Company derives its revenues from one source, the delivery of Nociscan reports to medical professionals. Substantially all revenues are generated from contracts with customers in the United States.

Executives

John Paul Lorbiecki	officer: Chief Financial Officer	238 CHEYENNE DRIVE, LAFAYETTE CO 80026
Brent Ness	director, officer: Chief Executive Officer	951 MARINERS ISLAND BLVD., SUITE 300, SAN MATEO CA 94404
Ryan Bond	officer: Chief Strategy Officer	951 MARINERS ISLAND BLVD., SUITE 300, SAN MATEO CA 94404
Stephen Deitsch	director	1600 BROADWAY, SUITE 700, DENVER CO 80202
William Wesemann	director	130 MONTALVO ROAD, REDWOOD CITY CA 94062
Jeffrey John Thramann	director, officer: Executive Chairman	8580 STRAWBERRY LANE, NIWOT CO 80503
Michael W Dirks	10 percent owner	811 EAST 30TH AVE, HUTCHINSON KS 67502
Nuvasive Inc	10 percent owner	7475 LUSK BLVD, SAN DIEGO CA 92121
Sc Capital 1 Llc	10 percent owner	1 COMPOUND DRIVE, HUTCHINSON KS 67502
Scott Breidbart	director	951 MARINERS ISLAND BLVD, SUITE 300, SAN MATEO CA 94404
Amanda Mae Sequira	director	951 MARINERS ISLAND BLVD., SUITE 300, SAN MATEO CA 94404
David K Neal	director	C/O ACLARION, INC., 951 MARINERS ISLAND BLVD, SUITE 300, SAN MATEO CA 94404